Note 3 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands |
3 Months Ended |
Sep. 30, 2016 |
Sep. 30, 2015 |
| Biotechnology [Member] | Operating Segments [Member] |
|
|
| Net sales |
$ 86,787
|
$ 75,743
|
| Operating income |
42,480
|
39,316
|
| Diagnostics [Member] | Operating Segments [Member] |
|
|
| Net sales |
24,233
|
20,362
|
| Operating income |
6,303
|
4,711
|
| Protein Platforms [Member] | Operating Segments [Member] |
|
|
| Net sales |
19,573
|
16,296
|
| Operating income |
209
|
(1,172)
|
| Operating Segments [Member] |
|
|
| Operating income |
48,992
|
42,855
|
| Intersegment Eliminations [Member] |
|
|
| Net sales |
(12)
|
(20)
|
| Corporate, Non-Segment [Member] |
|
|
| Corporate general and administrative |
(1,582)
|
(965)
|
| Acquisition Related [Member] |
|
|
| Amortization expense |
(10,188)
|
(7,411)
|
| Net sales |
130,581
|
112,381
|
| Operating income |
25,442
|
31,028
|
| Cost recognized on sale of acquired inventory |
(4,219)
|
(1,113)
|
| Amortization expense |
(10,188)
|
|
| Acquisition related expenses |
(4,369)
|
(301)
|
| Stock-based compensation |
(3,176)
|
(2,038)
|
| Corporate general and administrative |
$ (46,263)
|
$ (33,040)
|